Federal Register #2026-18954

Monoclonal Antibody Targeting RSV G Protein Available for Licensing from NIH/NIAID

This opportunity from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), offers a government-owned monoclonal antibody invention for commercial licensing and collaborative research. - Government Buyer: - National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID) - Technology Transfer and Intellectual Property Office - OEMs and Vendors: - NIAID (as the developer and owner of the invention) - Products/Services Requested: - Monoclonal antibody targeting the Respiratory Syncytial Virus (RSV) G protein - Part number: E11720240 - Subclasses: IgG3 and IgG1 - IgG3 form demonstrates approximately 9-fold greater neutralizing activity than existing licensed RSV antibodies - No specific purchase quantity; this is a licensing opportunity - Unique/Notable Requirements: - Technology is available for commercial development or collaborative research - Intellectual property includes provisional and PCT patent applications - Antibody may be used alone or in combination with current RSV F-targeting antibodies to broaden protection - Focus is on licensing, not procurement of physical products

Description

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), announces the availability of a government-owned invention for licensing. The invention is a monoclonal antibody targeting the Respiratory Syncytial Virus (RSV) G protein, which shows high neutralizing potency and potential for development as a first-in-class antibody for prevention or treatment of RSV disease. This technology aims to support commercialization of federally funded research results and may be licensed for commercial development or research collaboration. The antibody targets a conserved region of the RSV G protein and may be used alone or in combination with existing RSV F-targeting antibodies to broaden protection.

View original listing